James Metz, MD
OncoLink Associate Editor
Ultima Vez Modificado: 1 de noviembre del 1999
Presenter: Christoph M. Glaser, MD
Affiliation: General Hospital Vienna, Austria
Anemia is a frequent finding in patients with head and neck cancer and has been found to be a poor prognostic factor. This study was performed to evaluate the impact of r-HuEPO on patients with a low Hgb level.
All 187 patients in this retrospective study received neoadjuvant chemoradiation therapy prior to surgical resection of their head and neck cancer. Patients were divided into 3 groups: Group 1 had a Hgb > 14.5 g/dl and received no r-HuEPO (1990-1998), Group 2 (1990-1996) and Group 3 (1996-1998) had Hgb <14.5 g/dl but only Group 3 was treated with r-HuEPO.
ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.